Side Effects of Slow-Releasing Tegafur Capsule (Sunfural ® S) in Oral Squamous Cell Carcinoma Patients

Atsushi Fukagawa, Masanori Shinohara, Seiji Nakamura, Makoto Shimada, Masuichiro Oka

Research output: Contribution to journalArticlepeer-review


Adjuvant chemotherapy has recently become an effective measure for treatment of malignant tumors. Sunfural®F S is a slow-releasing Tegafur capsule, which is a masked compound of 5- FU, and was developed for the purpose of elevating the effect and reducing the side effects of Tegafur. We report here side effects of Sunfural®F S possibly caused by the long-term administration of this agent to 26 oral S.C.C.C patients. Side effects were seen in 9 patients (34.6 %). Two patients experienced two different side effects. Liver dysfunction in 3 cases, loss of appetite in 2 cases, pigmentation in 2 cases, eruption, photosensitivity, decrease of WBC, or decrease of platelets in 1 case. The occurrence of these side effects showed no relevance to patients' age, sex, dosage, or duration of administration. All patients recovered in several weeks after the administration had been stopped. These results suggested the usefulness and the safety of Sunfural®F S as an adjuvant chemotherapeutic agent.

Original languageEnglish
Pages (from-to)91-95
Number of pages5
Issue number2
Publication statusPublished - Mar 1993

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • General Dentistry
  • Pharmacology


Dive into the research topics of 'Side Effects of Slow-Releasing Tegafur Capsule (Sunfural ® S) in Oral Squamous Cell Carcinoma Patients'. Together they form a unique fingerprint.

Cite this